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Background. People living with human immunodeficiency virus (PLWH) are still being diagnosed late, rendering the benefits 
of “early” antiretroviral therapy (ART) unattainable. Therefore, we aimed to evaluate the benefits of “immediate” ART.
Methods. A nationwide cohort of PLWH in China who initiated ART January 1, 2011, to December 31, 2014 and had baseline 
CD4 results >200 cells/μL were censored at 12 months, dropout, or death, whichever came first. Treatment dropout and virological 
failure (viral load ≥400 copies/mL) were measured. Determinants were assessed by Cox and log-binomial regression.
Results. The cohort included 123 605 PLWH. The ≤30 days group had a significantly lower treatment dropout rate of 6.72%, 
compared to 8.91% for the 91–365 days group and to 12.64% for the >365 days group. The ≤30 days group also had a significantly 
lower virological failure rate of 5.45% (31–90 days: 7.39%; 91–365 days: 9.64%; >365 days: 12.67%). Greater risk of dropout (91–
365 days: adjusted hazard ratio [aHR] = 1.33, 95% confidence interval [CI] = 1.25–1.42; >365 days: aHR = 1.55, CI = 1.47–1.54), and 
virological failure (31–90 days: adjusted risk ratio [aRR] = 1.35, CI = 1.26–1.45; 91–365 days: aRR = 1.66, CI = 1.55–1.78; >365 days: 
aRR = 1.85, CI = 1.74–1.97) were observed for those who delayed treatment.
Conclusions. ART within 30 days of HIV diagnosis was associated with significantly reduced risk of treatment failure, highlight-
ing the need to implement test-and-immediately-treat policies.
Keywords. HIV/AIDS; antiretroviral therapy; treatment dropout; virological failure; China.
The benefits of “early” antiretroviral therapy (ART) initia-
tion when CD4 counts are still high are well accepted. Studies 
have shown reduced risk of clinical events, increased odds of 
virological suppression, and prolonged survival [1, 2], as well 
as reduced risk of tuberculosis and some cancers [3, 4], and 
decreased sexual and mother-to-child transmission [5–7]. 
Thus, early ART is now recommended for all people living 
with human immunodeficiency virus (PLWH) [8, 9]. However, 
in real-world settings, many PLWH continue to be diagnosed 
late. These “late presenters” already have low CD4 counts and 
thereby have missed the opportunity to receive “early” ART. 
Therefore, in many settings, the focus has turned from “early” 
to “immediate” ART [2, 10–12], or ART initiation quickly after 
diagnosis, regardless of CD4 count.
Several projects in China have strived for earlier human 
immunodeficiency virus (HIV) diagnosis, faster ART initi-
ation, and better retention in care, by expanding testing and 
treatment and streamlining the care cascade. Newly diagnosed 
PLWH were encouraged to promptly initiate ART regardless 
of CD4 count despite national guidelines restricting ART eli-
gibility by CD4 level until early 2016. One study since found 
that time from diagnosis to ART initiation was reduced to a 
median of 5 days, ART initiation rose to 91% within 1 year, and 
mortality fell by 62% [13]. In another study, odds of achieving 
testing completeness (HIV, CD4, and viral load [VL] testing) 
within 30 days increased 20-fold, odds of initiating ART within 
90  days increased 3.5-fold, and mortality declined by nearly 
60% [14].
We hypothesized that immediate ART would reduce treat-
ment dropout and virological failure, and we conducted a 
nationwide cohort study of patients in China’s National Free 
ART Program (NFATP) to evaluate these outcomes and their 
determinants.
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METHODS
Design
A nationwide observational cohort study was conducted among 
NFATP patients who initiated ART between January 1, 2011, 
and December 31, 2014. Figure  1 describes the study design. 
For each participant, the beginning of follow-up was the date of 
first ART initiation. All were followed until the date of dropout, 
death, or 12-month follow-up, whichever came first. The study 
ended December 31, 2015.
Enrolment
All individuals who had records of first ART initiation between 
January 1, 2011, and December 31, 2014 were screened for eli-
gibility. Criteria were (a) age ≥18 years on date of first ART ini-
tiation, (b) HIV infection route self-reported as sexual contact 
or injecting drug use, and (c) baseline CD4 count ≥200 cells/μL. 
PLWH with CD4 <200 cells/μL were not eligible because of their 
increased odds of rapid ART uptake due to severe symptoms. 
Participants were excluded for inability to link their records 
between the 2 databases or for having no follow-up records.
Data
Data were extracted from China’s HIV/AIDS Comprehensive 
Response Information Management System (CRIMS) [15], a 
nationwide, real-time, reporting system that is controlled and 
maintained by the National Center for AIDS/STD Control 
and Prevention (NCAIDS) of the Chinese Center for Disease 
Control and Prevention (China CDC). In China, all new cases 
of confirmed HIV infection require CRIMS reporting. CRIMS 
has been described elsewhere [15], but in brief, records include 
demographics, HIV test dates, transmission routes, and CD4 
test dates and results.
Upon initiation of ART, information must be reported into 
the NFATP Data System, a subsystem of CRIMS also con-
trolled and maintained by NCAIDS, China CDC. Although 
the NFATP and its data system have been described previously 
[16–18], 2 important programmatic changes occurred during 
the study period in 2012. First, tenofovir disoproxil fumarate 
(TDF) was recommended for first-line ART regimens. Second, 
although the CD4 count-based ART eligibility criterion was 
≤350 cells/μL over the entire study period, an exception for 
pregnant women, serodiscordant couples, and individuals with 
tuberculosis or hepatitis B coinfection was made, and these 
individuals were encouraged to begin ART regardless of CD4 
level. NFATP Data System records include ART initiation dates, 
details of ART regimens, CD4 test dates and results, and VL test 
dates and results.
According to standard practice in China during our study, 
free CD4 testing was performed at treatment baseline and 
then repeated every 6–12  months after ART initiation. After 
Figure 1. Study design and cohort development. All individuals newly enrolled in ART between January 1, 2011 and December 31, 2014 were screened. Participants were 
categorized into 4 subgroups: the ≤ 30 days group (ART initiation ≤ 30 days after HIV diagnosis), the 31–90 days group (ART initiation 31–90 days after HIV diagnosis), the 
91–365 days group (ART initiation 91–365 days after HIV diagnosis), and the >365 days group (ART initiation >365 days after HIV diagnosis). Outcomes were treatment 
dropout and virological failure (VL ≥400 copies/mL) at 12-months follow-up. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; VL, viral load.
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ART initiation, clinical follow-ups were performed at 2 weeks, 
1 month, 2 months, 3 months, and every 3 months thereafter. 
Free VL testing was performed once every 12 months after ART 
initiation. Study data were extracted on June 30, 2016.
Subgroups
All participants were categorized into 4 groups based on their 
time interval from the date of HIV diagnosis and the date of 
first ART initiation. Patients who initiated ART within 30 days 
of HIV diagnosis were categorized as the “≤30  days group.” 
Patients who initiated ART after 30  days but within 90  days 
were categorized as the “31–90 days group.” Patients who ini-
tiated ART after 90 days but within 1 year were categorized as 
the “91–365  days group.” Finally, patients who initiated ART 
after 1 year were categorized as the “>365 days group.” The first 
outcome, treatment dropout, was assessed after this initial cate-
gorization. Subsequently, only those remaining in the cohort at 
the end of the 12-month follow-up period (i.e., those who did 
not dropout or die), and had VL test results, were again cate-
gorized into the “≤30 days group,” the “31–90 days group,” the 
“91–365 days group,” and the “>365 days group” for assessment 
of the second outcome, virological failure (Figure 1).
Outcomes
Treatment dropout events were defined as loss to follow-up or 
discontinuation of ART within 12 months after first ART initi-
ation. Patients were censored at death or at last follow-up or at 
the end of the 12-month follow-up period. Virological failure 
was defined as VL ≥400 copies/mL at between 6 and 18 months 
after ART initiation. Because ART patients in China were pro-
vided free VL testing only once each year after ART initiation, 
we expanded the observational window for the virological fail-
ure outcome to ensure that we captured at least one VL test result 
for each participant. For those who had more than one VL test 
result during this window, the result nearest the 12-month fol-
low-up date was selected. Determinants of treatment dropout 
and virological failure were also assessed.
Analysis
Main Analyses
Continuous variables were summarized using median and 
interquartile range (IQR) and categorical variables using 
number and percent. Characteristics of participants were 
compared using rank-sum test for continuous variables and 
χ2 test for categorical variables. First ART initiation date was 
subtracted from latest censored date to calculate observed 
time, which was expressed in person-years (PY). Cox propor-
tional hazards regression was used to assess determinants of 
treatment dropout, generating hazard ratios (HRs) and 95% 
confidence intervals (CIs). Univariate and multivariate log-bi-
nomial regression models were used to assess determinants 
of virological failure, producing risk ratios (RRs) and CIs. All 
P-values were 2-sided, and P < .05 was considered statistically 
significant.
Post hoc Analyses
We performed 3 additional analyses. First, to evaluate whether 
there was any additional benefit to ART initiation in intervals 
less than 30 days, we divided the ≤30 days group into 3 smaller 
groups: ≤1  day, 2–7  days, and 8–30  days, and present treat-
ment dropout and virological failure rates. Second, to evaluate 
whether outcomes were different for those who initiated ART 
at higher CD4 counts, we created a subgroup with baseline CD4 
count results >350 cells/μL and present treatment dropout and 
virological failure rates stratified by time interval from diag-
nosis to treatment. Finally, to evaluate virological failure using 
an “intent-to-treat” (ITT) approach, all individuals who either 
died or dropped out of treatment were included as failures, and 
ITT virological failure rates are presented stratified by baseline 
CD4 count and time interval from diagnosis to treatment.
All statistical analyses were performed using SAS software 
(version 9.1.3, SAS Institute Inc., USA).
Ethics
This study was approved by the Institutional Review Board of 
NCAIDS, China CDC. All NFATP patients signed an informed 
consent upon entry. No additional informed consent was 
sought. All records were de-identified prior to analysis.
RESULTS
A total of 256 486 individuals were screened for study eligibil-
ity, and a total of 123 605  (48.2%) were included in the study 
cohort (Figure 1). Characteristics of participants are shown in 
Table 1. Median age was 36 years (IQR: 28–46). A majority was 
male (70.5%) and reported that their HIV infection route was 
heterosexual contact (63.5%). Median baseline CD4 count was 
308 cells/μL (IQR: 257–379).
Among the 123 605 participants in our cohort, 28 883 (23.4%)
initiated ART within 30  days of HIV diagnosis (≤30  days 
group), whereas 21 918 (17.7%) initiated ART between 31 and 
90 days after HIV diagnosis (31–90 days group), 25 635 (20.7%) 
initiated ART between 91 and 365  days after HIV diagnosis 
(91–365 days group), and 47 169 (38.2%) initiated ART more 
than 365 days after HIV diagnosis (>365 days group; Figure 1, 
Table 1). Median time between HIV diagnosis and ART initi-
ation for the ≤30 days group was 14 days (IQR: 7–21), for the 
31–90 days group was 51 days (IQR: 40–67), for the 91–365 days 
group was 190  days (IQR: 132–264), and for the >365  days 
group was 998 days (IQR: 622–1649; data not shown).
Those in the ≤30 days group tended to be older (age >50: 26.4% 
vs 21.8% in the 31–90  days group, 19.0% in the 91–365  days 
group, and 10.6% in the >365 days group). A greater propor-
tion of those in the ≤30 days group reported their HIV infec-
tion route as heterosexual contact (73.0% vs 64.5%, 64.5%, and 
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56.6%), whereas a larger proportion of those in the >365 days 
group reported injecting drug use as their route of HIV infec-
tion (25.8% vs and 7.0% in the 91–365 days group, 3.4% in the 
31–90 days group, and 2.4% in the ≤30 days group). A greater 
proportion of those in the >365 days group had higher baseline 
CD4 counts (>350 cells/μL: 35.9% vs 30.4%, 25.8%, and 28.0%).
Treatment Dropout and Determinants
A total of 11 663 participants dropped out of treatment within 
the 12-month follow-up period (Figure  1). As shown in 
Table  2, the overall dropout rate for the entire study cohort 
was 9.44% (CI  =  9.27–9.60). Treatment dropout rate was 
lowest for the ≤30 days group at 6.72% (CI = 6.43–7.01) and 
the 31–90  days group at 6.73% (CI  =  6.39–7.06), followed 
by the 91–365 days group at 8.91% (CI = 8.56–9.26) and the 
>365  days group at 12.64% (CI  =  12.34–12.94). Details of 
treatment dropout rate overall and by time from diagnosis to 
treatment group stratified by participant characteristics can be 
found in Supplementary Table S1.
As shown in Table  3, 123 605 participants contributed 
114 475 PY of observed time, during which a total of 11 663 
participants dropped out of treatment, for an overall dropout 
rate of 10.19 per 100 PY. Significantly greater risk of dropout 
was found among those who were aged >50  years (adjusted 
HR [aHR] = 1.30, CI = 1.23–1.38), reported their route of HIV 
infection as heterosexual contact (aHR = 2.44, CI = 2.28–2.62) 
or injecting drug use (aHR = 5.31, CI = 4.94–5.71), had a base-
line CD4 count >350 cells/μL (aHR = 1.19, CI = 1.14–1.24), and 
were in the 91–365 days group (aHR = 1.33, CI = 1.25–1.42) or 
the >365 days group (aHR = 1.55, CI = 1.47–1.54).
Table 1. Characteristics of Participants 
Characteristics
Entire Study Cohort, 
N (%)
≤30 Days Group, 
N (%)
31–90 Days Group, 
N (%)
91–365 Days Group, 
N (%)
>365 Days Group, 
N (%) P  Value
Overall 123 605 (100) 28 883 (100) 21 918 (100) 25 635 (100) 47 169 (100)
Age, years
 Median (IQR) 36 (28–46) 39 (29–51) 37 (28–48) 36 (27–47) 35 (29–42) <.001
 18–30 39 887 (32.3) 8442 (29.9) 7301 (33.3) 9037 (35.3) 15 107 (32.0) <.001
 31–50 61 451 (49.7) 12 824 (44.4) 9847 (44.9) 11 723 (45.7) 27 057 (57.4)
 >50 22 267 (18.0) 7617 (26.4) 4770 (21.8) 4875 (19.0) 5005 (10.6)
Sex
 Male 87 161 (70.5) 20 133 (69.7) 16 278 (74.3) 18 592 (72.5) 32 158 (68.2) <.001
 Female 36 444 (29.5) 8750 (30.3) 5640 (25.7) 7043 (27.5) 15 011 (31.8)
HIV infection route
 Injecting drug use 15 405 (12.5) 700 (2.4) 735 (3.4) 1792 (7.0) 12 178 (25.8) <.001
 Homosexual contact 29 735 (24.1) 7103 (24.6) 7038 (32.1) 7312 (28.5) 8282 (17.6)
 Heterosexual contact 78 465 (63.5) 21 080 (73.0) 14 145 (64.5) 16 531 (64.5) 26 709 (56.6)
TB coinfection
 Yes 3105 (2.5) 507 (1.8) 614 (2.8) 761 (3.0) 1223 (2.6) <.001
 No 120 500 (97.5) 28 376 (98.2) 21 304 (97.2) 24 874 (97.0) 45 946 (97.4)
Hepatitis B coinfection
 Yes 8220 (6.7) 1851 (6.4) 1386 (6.3) 1549 (6.0) 3434 (7.3) <.001
 Yes 74 169 (60.0) 18 183 (63.0) 12 420 (56.7) 14 376 (56.1) 29 190 (61.9)
 Not tested 41 216 (33.3) 8849 (30.6) 8112 (37.0) 9710 (37.9) 14 545 (30.8)
Serodiscordant couple
 Yes 28 175 (22.8) 6495 (22.5) 4995 (22.8) 6146 (24.0) 10 539 (22.3) <.001
 No 95 430 (77.2) 22 388 (77.5) 16 923 (77.2) 19 489 (76.0) 36 630 (77.7)
Baseline CD4 count (cells/μL)
 Median (IQR) 308 (257–379) 298 (248–364) 297 (250–354) 309 (259–376) 319 (265–402) <.001
 200–350 85 220 (69.0) 20 784 (72.0) 16 264 (74.2) 17 844 (69.6) 30 328 (64.3) <.001
 >350 38 385 (31.0) 8099 (28.0) 5654 (25.8) 7791 (30.4) 16 841 (35.9)
Initial ART regimen
 TDF not included 75 827 (61.4) 16 650 (57.7) 13 869 (63.3) 16 888 (65.9) 28 420 (61.4) <.001
 TDF included 47 778 (38.6) 12 233 (42.3) 8049 (36.7) 8747 (34.1) 18 749 (38.6)
Year ART initiated
 2011 18 772 (15.2) 2840 (9.8) 2692 (12.3) 4346 (16.9) 8894 (18.9) <.001
 2012 25 454 (20.6) 5170 (17.9) 4510 (20.6) 5639 (22.0) 10 135 (21.5)
 2013 34 411 (27.8) 8118 (28.1) 6272 (28.6) 7099 (27.7) 12 922 (27.4)
 2014 44 968 (36.4) 12 755 (44.2) 8444 (38.5) 8551 (33.4) 15 218 (32.3)
Characteristics of the entire study cohort, and subgroups based on duration from diagnosis to ART initiation—the ≤30 days group, the 31–90 days group, the 91–365 days group, and the 
>365 days group—in China, 2011–2015.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range, TB, tuberculosis; TDF, tenofovir disoproxil fumarate.
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Virological Failure and Determinants
Among the 99 398 participants remaining in the cohort (i.e., 
excluding those who had not dropped out or died) who had VL test 
results, a total of 9235 had VL ≥400 copies/mL (Figure 1). As shown 
in Table 2, the overall virological failure rate was 9.29% (CI = 9.11–
9.47). Virological failure rate was lowest for the ≤30 days group at 
5.45% (CI = 5.17–5.73), followed by the 31–90 days group at 7.39% 
(CI = 7.01–7.77) and the 91–365 days group at 9.64% (CI = 9.24–
10.04), with the highest rate among the >365 days group at 12.67% 
(CI = 12.33–13.02). Details of virological failure rate overall and 
by time from diagnosis to treatment group stratified by participant 
characteristics can be found in Supplementary Table S2.
As shown in Table  4, greater risk of virological failure was 
found among those who reported their route of HIV infection 
as heterosexual contact (adjusted RR [aRR] = 1.78, CI = 1.67–
1.90) or injecting drug use (aRR = 4.08, CI = 3.81–4.73) and 
were in the 31–90  days group (aRR  =  1.35, CI  =  1.26–1.45), 
the 91–365  days group (aRR  =  1.66, CI  =  1.55–1.78), or the 
>365 days group (aRR = 1.85, CI = 1.74–1.97).
Results of post hoc analyses are also presented in Table  2. 
After further dividing the ≤30  days group into smaller time 
intervals, we found very little difference in treatment dropout 
rates and virological failure rates between the shorter time 
interval groups. Similarly, we found that compared to the entire 
study cohort, only small differences were observed in treatment 
dropout and virological failure rates for those with baseline 
CD4 results of >350 cells/μL. By contrast, when we reanalyzed 
the virological failure outcome using the ITT approach, we 
observed much higher virological failure rates—19.70% for the 
≤30 days group, 22.67% for the 31–90 days group, 27.43% for 
the 91–365 days group, and 33.39% for the >365 days group.
DISCUSSION
Our study revealed that those who initiated ART within 30 days 
after diagnosis had significantly reduced rates of treatment 
dropout and virological failure. Furthermore, those who initi-
ated ART in 31–90 days had a 35% greater risk of virological 
failure, those who initiated  in 91–365 days had a 33% greater 
risk of treatment dropout and 66% greater risk of virological 
failure, and finally, those who initiated ART in >365 days had 
a 55% greater risk of dropout and an 85% greater risk of viro-
logical failure. Notably, individuals in our delayed ART groups 
tended to be middle-aged, injecting drug users, and/or have 
higher CD4 counts, factors that may have influenced their abil-
ity to access care. Nevertheless, this reflects real-world condi-
tions in China. We also noticed that individuals infected via 
heterosexual contact had 2.44 times greater risk of dropout and 
1.78 times greater risk of virological failure, compared to those 
infected via homosexual contact. It is possible that homosexu-
als in urban areas, have better access to care, and have a better 
compliance.
Our findings add important additional dimensions to two 
recent studies of interventions meant to accelerate time from 
testing to treatment in China. The results of those studies were 
dramatically increased rates of timely diagnosis and thorough 
clinical assessment, substantially reduced time from diagnosis to 
ART initiation, significantly greater rates of ART initiation, and 
meaningfully improved survival [13, 14]. Furthermore, an even 
more recent nationwide cohort study of PLWH who had baseline 
CD4 counts >500 cells/μL found that those who entered China’s 
NFATP and immediately initiated ART (≤30  days after diag-
nosis, compared to >30 days) experienced 63% lower mortality 
[19]. Thus, the benefit of immediate ART is meaningful, even for 
those who are not diagnosed late. Of note, another recent study in 
China found that those with CD4 counts >500 cells/μL at baseline 
had greater probability of attrition (i.e., loss to follow-up or ART 
cessation), suggesting that these patients may require additional 
support to promote retention in care over time [20].
Consistent with our study, a clinical trial of a new rapid ART 
initiation algorithm (ART in a single clinic visit) in South Africa 
Table 2. Main Outcome Measures and Results of Post hoc Analyses 
Time From 
Diagnosis to 
Treatment
Entire Cohort (Baseline CD4 >200 Cells/μL) Subgroup Including Only Those With Baseline CD4 >350 Cells/μL
Treatment Dropout 
Rate, % (CI)
Virological Failure 
Rate, % (CI)
Intent-to-Treat Virological 
Failure Rate, % (CI)
Treatment Dropout 
Rate, % (CI)
Virological Failure 
Rate, % (CI)
Intent-to-Treat Virological 
Failure Rate, % (CI)
1 day group 7.86 (6.50–9.22) 4.58 (3.43–5.73) 19.45 (17.45–21.46) 8.56 (6.14–10.98) 5.07 (3.01–7.13) 19.84 (16.40–23.29)
2–7 days group 7.45 (6.79–8.11) 5.56 (4.94–6.19) 20.61 (19.59–21.63) 8.72 (7.47–9.96) 5.40 (4.31–6.50) 20.59 (18.80–22.38)
8–30 days group 6.43 (6.10–6.76) 5.48 (5.15–5.81) 19.46 (18.93–19.99) 7.90 (7.19–8.60) 5.18 (4.55–5.81) 19.31 (18.28–20.35)
≤30 days group 6.72 (6.43–7.01) 5.45 (5.17–5.73) 19.70 (19.24–20.16) 8.14 (7.54–8.73) 5.23 (4.70–5.76) 19.66 (18.79–20.52)
31–90 days group 6.73 (6.39–7.06) 7.39 (7.01–7.77) 22.67 (22.11–23.22) 7.53 (6.85–8.22) 6.70 (5.99–7.41) 21.65 (20.57–22.72)
91–365 days group 8.91 (8.56–9.26) 9.64 (9.24–10.04) 27.43 (26.88–27.97) 9.49 (8.83–10.14) 9.11 (8.40–9.83) 26.79 (25.80–27.77)
>365 days group 12.64 (12.34–12.94) 12.67 (12.33–13.02) 33.39 (32.97–33.82) 14.04 (13.51–14.56) 13.69 (13.10–14.29) 34.74 (34.02–35.46)
Overall 9.44 (9.27–9.60) 9.29 (9.11–9.47) 27.06 (26.81–27.30) 10.91 (10.60–11.22) 9.77 (9.44–10.11) 28.01 (27.56–28.46)
Main outcome measures of treatment dropout and virological failure overall and for the ≤30 days group, the 31–90 days group, the 91–365 days group, and the >365 days group is presented 
inside the red box. Post hoc analyses for the entire cohort as well as only those participants with baseline CD4 count results >350 cells/mm3, and assessed at a range of earlier time points 
are also presented.
Abbreviation: CI, confidence interval.
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observed both an increase in retention and in viral suppression 
at 10 months follow-up [21]. A study in rural Uganda and Kenya 
found that delay in ART initiation of more than 30 days after 
HIV diagnosis was associated with elevated rates of treatment 
dropout at 12 months [22]. In Myanmar, 94% of ART-eligible 
study participants were on ART by 90 days, and only 3% had 
dropped out of treatment in a median of 13 months of follow-up 
[23]. A  very large, retrospective analysis of newly diagnosed 
PLWH in high-income countries has found that immediate ini-
tiation of ART increases viral suppression earlier in follow-up 
[24]. Finally, a smaller study of a same-day ART intervention 
in the United States found reduced time to virological suppres-
sion [25]. We believe that in the China context, immediate ART 
eliminates the chance that newly diagnosed PLWH receive con-
fusing or incorrect messages about HIV/AIDS treatment and 
care, a problem known to contribute to losses to follow-up in 
the pre-ART period.
These results from around the globe make a good case for 
movement to test-and-immediately-treat policies. However, 
implementation will be challenging. For China, this means 
that some 200 000 diagnosed but untreated PLWH should be 
started on ART as quickly as possible. Streamlining of the HIV 
care cascade will be required. To cope with increased demand 
for HIV services, China’s NFATP will again need to be rapidly 
scaled up. Moreover, close surveillance of HIV VL in ART 
patients via regular testing will be important for early detection 
Table 3. Determinants of Treatment Dropout 
Characteristics
Entire Cohort, 
N
Observed Time, 
PY Dropped Out, N
Dropout Rate, 
per 100 PY Unadjusted HR (CI) P  Value Adjusted HR (CI) P  Value
Overall 123 605 114 475 11 663 10.19
Age, years
 18–30 39 887 37 545 3386 9.02 1.00 1.00
 31–50 61 451 56 911 5883 10.34 1.14 (1.09–1.19) <.001 0.90 (0.86–0.94) <.001
 >50 22 267 20 019 2394 11.96 1.31 (1.25–1.38) <.001 1.30 (1.23–1.38) <.001
Sex
 Male 87 161 80 716 8056 9.98 0.93 (0.90–0.97) <.001 1.05 (1.01–1.10) .061
 Female 36 444 33 759 3607 10.68 1.00 1.00
HIV infection route
 Homosexual contact 29 735 28 887 1142 3.95 1.00 1.00
 Heterosexual contact 78 465 72 460 7402 10.22 2.55 (2.40–2.72) <.001 2.44 (2.28–2.62) <.001
 Injecting drug use 15 405 13 128 3119 23.76 5.79 (5.41–6.19) <.001 5.31 (4.94–5.71) <.001
TB coinfection
 Yes 3105 2780 355 12.77 1.25 (1.12–1.39) <.001 1.06 (0.95–1.17) .32
 No 120 500 111 695 11 308 10.12 1.00 1.00
Hepatitis B coinfection
 Yes 41 216 38 158 3683 9.65 1.00 1.00
 No 8220 7660 739 9.65 1.09 (1.01–1.18) .022 1.15 (1.06–1.24) .001
 Not tested 74 169 68 656 7241 10.55 1.00 (0.92–1.08) .998 1.10 (1.01–1.19) .022
Serodiscordant couple
 Yes 28 175 26 113 2630 10.07 1.00 1.00
 No 95 430 88 362 9033 10.22 1.01 (0.97–1.06) .522 1.10 (1.06–1.15) <.001
Baseline CD4 count (cells/μL)
 200–350 85 220 79 217 7475 9.44 1.00 1.00
 >350 38 385 35 258 4188 11.88 1.26 (1.21–1.30) <.001 1.19 (1.14–1.24) <.001
Initial ART regimen
 TDF not included 75 827 70 074 7346 10.48 1.08 (1.04–1.12) <.001 1.21 (1.16–1.26) <.001
 TDF included 47 778 44 401 4317 9.72 1.00 1.00
Year ART initiated
 2011 18 772 17 466 1764 10.10 1.00 1.00
 2012 25 454 23 515 2513 10.69 1.06 (1.00–1.13) .082 1.18 (1.11–1.25) <.001
 2013 34 411 31 439 3805 12.10 1.20 (1.13–1.27) <.001 1.43 (1.35–1.52) <.001
 2014 44 968 42 055 3581 8.52 0.85 (0.80–0.90) <.001 1.13 (1.06–1.20) <.001
Time of ART initiation
 ≤30 days group 28 883 27 285 1941 7.11 1.00 1.00
 31–90 days group 21 918 20 699 1474 7.12 1.00 (0.94–1.07) .983 1.05 (0.99–1.13) .13
 91–365 days group 25 635 23 819 2284 9.58 1.34(1.26–1.43) <.001 1.33 (1.25–1.42) <.001
 >365 days group 47 169 42 672 5964 13.98 1.94 (1.84–2.04) <.001 1.55 (1.47–1.54) <.001
Treatment dropout, observed time, dropout rate, and determinants of treatment dropout as assessed by Cox regression modeling in China, 2011–2015.
Abbreviations: ART, antiretroviral therapy; CI, 95 % confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; PY, person-years; TB, tuberculosis; TDF, tenofovir disoproxil 
fumarate. 
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of virological failure and prompt switching to second-line ther-
apy. Dramatic scale up of VL testing capacity and aggressive 
pursuit of new point-of-care technologies allowing decentral-
ization and increased coverage will be needed. Finally, an esti-
mated 300 000 PLWH in China still do not know their status 
[26]. China must redouble its case-finding efforts to help these 
people get the care they need.
Our study had some limitations. First, our study was con-
ducted among subjects in routine HIV care. Thus, participants 
were not randomly assigned to groups, creating potential for 
bias. Second, missing values for some variables in our data set 
could have resulted in under- or overestimation of the outcomes 
of interest. Third, although unlikely, it is possible that some 
misclassification bias occurred, due to treatment interruptions 
or unascertained deaths being counted as dropouts. If an indi-
vidual stopped and restarted ART during our 12-month fol-
low-up period, they were still counted as on ART at 12 months. 
Moreover, all deaths among PLWH in China are recorded in 
CRIMS, causing them to be classified as died, not dropped out.
Our results demonstrate that immediate ART is associated 
with reduced treatment dropout and virological failure. Taken 
together with the results of other recent studies in China [13, 
14, 19], and other settings [21–25, 27], it is clear that shorten-
ing the time from diagnosis to treatment maximizes health and 
survival and should be an urgent priority. Moreover, movement 
toward a test-and-immediately-treat policy could help China 
Table 4. Determinants of Virological Failure 
Characteristics Virological Failure, N (%) Unadjusted RR (CI) P  Value Adjusted RR (CI) P  Value
Overall 9235 (100)
Age, years
 18–30 2764 (29.9) 1.00 1.00
 31–50 4767 (51.6) 1.15 (1.10–1.20) .002 0.91 (0.87–0.95) <.001
 >50 1704 (18.5) 1.18 (1.11–1.25) <.001 1.17 (1.10–1.24) <.001
Sex
 Male 6574 (71.2) 1.05 (1.00–1.09) .030 1.14 (1.09–1.19) <.001
 Female 2661 (28.8) 1.00 1.00
HIV infection route
 Homosexual contact 1344 (14.6) 1.00 1.00
 Heterosexual contact 5713 (61.9) 1.78 (1.68–1.88) <.001 1.78 (1.67–1.90) <.001
 Injecting drug use 2178 (23.6) 4.47 (4.19–4.76) <.001 4.08 (3.81–4.73) <.001
TB coinfection
 Yes 268 (2.9) 1.26 (1.12–1.41) <.001 1.05 (0.94–1.18) .38
 No 8967 (97.1) 1.00 1.00
Hepatitis B coinfection
 Yes 656 (7.1) 1.00 1.00
 No 4873 (52.8) 0.81 (0.75–0.88) <.001 0.83 (0.77–0.89) <.001
 Not tested 3706 (40.1) 1.15 (1.06–1.24) <.001 1.18 (1.09–1.28) <.001
Serodiscordant couple
 Yes 2307 (25.0) 1.00 1.00
 No 6928 (75.0) 0.89 (0.85–0.93) <.001 0.95 (0.91–1.00) .038
Baseline CD4 count (cells/μL)
 200–350 6204 (67.2) 1.00 1.00
 >350 3031 (32.8) 1.08 (1.03–1.12) <.001 1.07 (1.03–1.12) .002
Initial ART regimen
 TDF not included 6201 (67.1) 1.30 (1.25–1.36) <.001 1.34 (1.28–1.40) <.001
 TDF included 3034 (32.9) 1.00 1.00
Year ART initiated
 2011 1771 (19.2) 1.00 1.00
 2012 1964 (21.3) 0.81 (0.76–0.86) <.001 0.92 (0.87–0.98) .009
 2013 2499 (27.1) 0.78 (0.74–0.83) <.001 1.00 (0.94–1.06) .90
 2014 3001 (32.5) 0.69 (0.65–0.73) <.001 0.99 (0.93–1.05) .74
Time of ART initiation
 ≤30 days 1337 (14.5) 1.00 1.00
 31–90 days 1353 (14.7) 1.36 (1.26–1.46) <.001 1.35 (1.26–1.45) <.001
 91–365 days 1985 (21.5) 1.77 (1.65–1.89) <.001 1.66 (1.55–1.78) <.001
 >365 days 4560 (49.4) 2.33 (2.19–2.47) <.001 1.85 (1.74–1.97) <.001
Virological failure and determinants of virological failure as assessed by univariate and multivariate log binomial regression modeling in China, 2011–2015.
Abbreviations: ART, antiretroviral therapy; CI, 95% confidence interval; HIV, human immunodeficiency virus; RR, risk ratio; TB, tuberculosis; TDF, tenofovir disoproxil fumarate. 
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meet the UNAIDS 90-90-90 targets, if it can overcome the many 
implementation challenges.
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